Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX4 plus cetuximab versus FOLFOX4 as first-line therapy in EGFR-expressing metastatic colorectal cancer
2005-000970-37Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Best confirmed response. Started Jun 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2005-000970-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000970-37.